Citalopram and escitalopram carry the highest risk of QT prolongation among SSRIs. The remaining SSRIs, including fluoxetine, fluvoxamine, sertraline, and paroxetine, all have a lower and roughly similar risk profile, with paroxetine appearing to be the safest option for the heart’s electrical rhythm.
How SSRIs Are Ranked by Risk
SSRIs affect the heart’s electrical cycle by interfering with potassium channels that help heart muscle cells reset between beats. When these channels are blocked, each heartbeat takes slightly longer to complete its electrical cycle, stretching the QT interval on an ECG. The degree to which each SSRI does this varies considerably.
Known risk (highest): Citalopram and escitalopram are both classified as having a “known risk” of torsades de pointes, a dangerous heart rhythm that can result from excessive QT prolongation. Both show dose-dependent effects, meaning higher doses produce larger changes in the QT interval. In a thorough QT study, escitalopram extended the QT interval by about 4.3 milliseconds at 10 mg per day and by 10.7 milliseconds at 30 mg per day.
Conditional risk (lower): Fluoxetine, fluvoxamine, sertraline, and paroxetine are all classified as having only a “conditional risk,” meaning QT prolongation typically requires additional factors like drug interactions, overdose, or electrolyte problems. Among these four, paroxetine appears to carry the lowest cardiac risk. Fluoxetine, fluvoxamine, and sertraline cluster together with similar, low-level effects on the QT interval.
A large study of over 65,000 patients on hemodialysis (a group already vulnerable to heart rhythm problems) found that those taking citalopram or escitalopram had a higher rate of sudden cardiac death compared to those taking the other four SSRIs. The difference was especially pronounced in patients over 65, women, and people with pre-existing heart conduction problems.
Why Citalopram Has Specific Dose Limits
Citalopram is the only SSRI with an FDA-imposed dose ceiling specifically because of QT concerns. The maximum recommended dose is 40 mg per day for most adults. For patients over 60, those with liver problems, and those who metabolize the drug slowly due to genetic variation, the ceiling drops to 20 mg per day. These restrictions exist because all of those factors raise blood levels of the drug, amplifying its effect on the QT interval.
Importantly, escitalopram is not necessarily a safe swap. Though it’s the active mirror-image molecule of citalopram and is given at lower doses, it still demonstrates dose-dependent QT prolongation. One review concluded that when citalopram is avoided due to cardiac risk factors, escitalopram “is not likely the safest alternative.”
When Lower-Risk SSRIs Still Cause Problems
Even SSRIs classified as lower risk can prolong the QT interval under certain conditions. Fluoxetine, for example, blocks the same potassium channels that citalopram does, just less potently at normal blood levels. At therapeutic doses, the free drug concentration in the blood is generally too low to meaningfully impair these channels. But in overdose, the effect can be dramatic: one case report documented a QTc of 625 milliseconds (normal is under 450 for men, 460 for women) in a young woman who intentionally overdosed on fluoxetine. Her QTc returned to a normal 400 milliseconds three weeks later.
The conditions that can tip a lower-risk SSRI into dangerous territory include overdose, taking other medications that also prolong the QT interval, genetic heart rhythm disorders, very low potassium or magnesium levels, and impaired liver function that slows drug metabolism.
Risk Factors That Compound the Danger
QT prolongation from an SSRI rarely happens in isolation. It almost always involves a combination of the drug plus one or more additional risk factors. The major ones include:
- Age over 65
- Female sex (women naturally have slightly longer QT intervals)
- Low potassium, magnesium, or calcium levels, often caused by diuretics or kidney disease
- Heart failure or structural heart disease
- Existing conduction disorders or a history of arrhythmias
- Chronic kidney or liver disease
- Taking multiple QT-prolonging drugs at once
- Congenital long QT syndrome
A QTc interval above 500 milliseconds or an increase of more than 60 milliseconds from baseline are both considered red flags that significantly raise the risk of a dangerous arrhythmia.
Drug Combinations That Increase Risk
Taking an SSRI alongside another medication that stretches the QT interval creates an additive effect. This is especially relevant because many people on antidepressants also take antipsychotics, and several antipsychotics independently prolong the QT interval. In a study of elderly psychiatric outpatients, the most common problematic drug pairs were escitalopram with risperidone, escitalopram with olanzapine, and fluoxetine with olanzapine. Escitalopram appeared in the greatest number of QT-prolonging drug interactions overall.
Beyond antipsychotics, certain antibiotics (like ciprofloxacin), anti-nausea medications (like domperidone), and antimalarials also prolong the QT interval and can interact dangerously with SSRIs. If you’re taking citalopram or escitalopram and are prescribed any new medication, it’s worth checking whether the combination raises cardiac risk.
How Rare Is a Dangerous Arrhythmia?
Actual cases of torsades de pointes from SSRIs are rare. A systematic review of the entire medical literature found only 15 published case reports linking SSRIs to this arrhythmia: eight involved citalopram, six involved fluoxetine, and one involved sertraline. Of the 13 cases with detailed information, 12 were women. The overall odds ratio for SSRIs and out-of-hospital cardiac arrest was 1.21, a modest increase in risk driven primarily by citalopram (odds ratio 1.29).
This matters for perspective. QT prolongation on an ECG is relatively common with citalopram and escitalopram, but the progression to a life-threatening arrhythmia is uncommon. The risk becomes meaningful when multiple factors stack together: an older woman on citalopram who develops low potassium from a diuretic while also taking an antipsychotic, for instance, faces a very different risk profile than a young man on sertraline alone.
Choosing a Safer Option
For people who have cardiac risk factors or are already taking other QT-prolonging medications, sertraline and paroxetine are generally the preferred SSRIs. Sertraline in particular has a long track record of cardiac safety research, and paroxetine consistently appears at the bottom of the QT risk rankings. Fluoxetine and fluvoxamine are also reasonable choices, though fluoxetine’s tendency to inhibit liver enzymes can raise blood levels of other medications, indirectly contributing to QT risk through drug interactions.
Most SSRIs are classified as low-risk cardiac medications, and for people without specific risk factors, a baseline ECG is not routinely required before starting treatment. When multiple risk factors for QT prolongation are present, an ECG before and after starting the medication helps establish whether the drug is affecting heart rhythm in a clinically meaningful way.